Study provides insights into the molecular mechanism of Batten disease

Ab­b­Vie moved ahead with its $10.1 bil­lion ac­qui­si­tion of an­ti­body-drug con­ju­gate biotech Im­muno­Gen, while Bris­tol My­ers Squibb’s big ac­qui­si­tion of ra­dio­phar­ma­ceu­ti­cals biotech Rayze­Bio is like­ly

The FDA ap­proved a Hous­ton drug­mak­er’s tablet for adults with ma­jor de­pres­sive dis­or­der last week, cap­ping a decades-long back-and-forth be­tween mul­ti­ple com­pa­nies and the reg­u­la­tor